Syndax Pharmaceuticals Future Growth

Future criteria checks 2/6

Syndax Pharmaceuticals is forecast to grow earnings and revenue by 24.4% and 43.9% per annum respectively. EPS is expected to grow by 26.3% per annum. Return on equity is forecast to be -46.3% in 3 years.

Key information

24.4%

Earnings growth rate

26.3%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	43.9%
Future return on equity	-46.3%
Analyst coverage	Good
Last updated	21 Nov 2024

Recent future growth updates

Recent updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

Earnings and Revenue Growth Forecasts

NasdaqGS:SNDX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	248	-237	-167	-169	12
12/31/2025	99	-333	-230	-267	13
12/31/2024	149	-240	-284	-196	13
9/30/2024	16	-297	-259	-259	N/A
6/30/2024	4	-264	-241	-241	N/A
3/31/2024	N/A	-241	-205	-205	N/A
12/31/2023	N/A	-209	-161	-161	N/A
9/30/2023	N/A	-176	-142	-142	N/A
6/30/2023	N/A	-160	-126	-126	N/A
3/31/2023	N/A	-153	-131	-131	N/A
12/31/2022	N/A	-149	-134	-134	N/A
9/30/2022	127	-14	-10	-10	N/A
6/30/2022	139	1	-7	-6	N/A
3/31/2022	139	15	10	10	N/A
12/31/2021	140	25	29	29	N/A
9/30/2021	14	-92	-87	-87	N/A
6/30/2021	2	-91	-81	-81	N/A
3/31/2021	2	-86	-78	-78	N/A
12/31/2020	2	-77	-71	-71	N/A
9/30/2020	2	-71	-68	-68	N/A
6/30/2020	2	-63	-59	-59	N/A
3/31/2020	2	-61	-50	-50	N/A
12/31/2019	2	-56	-51	-51	N/A
9/30/2019	2	-61	-53	-53	N/A
6/30/2019	2	-65	-63	-63	N/A
3/31/2019	2	-69	-66	-65	N/A
12/31/2018	2	-74	-69	-69	N/A
9/30/2018	2	-74	-66	-66	N/A
6/30/2018	2	-72	N/A	-58	N/A
3/31/2018	2	-67	N/A	-55	N/A
12/31/2017	2	-61	N/A	-47	N/A
9/30/2017	1	-53	N/A	-45	N/A
6/30/2017	1	-52	N/A	-46	N/A
3/31/2017	1	-47	N/A	-41	N/A
12/31/2016	1	-47	N/A	-35	N/A
9/30/2016	1	-45	N/A	-29	N/A
6/30/2016	1	-87	N/A	-23	N/A
3/31/2016	1	-105	N/A	-20	N/A
12/31/2015	1	-104	N/A	-2	N/A
9/30/2015	0	-100	N/A	-2	N/A
6/30/2015	0	-53	N/A	1	N/A
3/31/2015	N/A	-33	N/A	1	N/A
12/31/2014	N/A	-26	N/A	-14	N/A
9/30/2014	N/A	-31	N/A	-14	N/A
6/30/2014	N/A	-72	N/A	-13	N/A
3/31/2014	N/A	-67	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNDX's revenue (43.9% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: SNDX's revenue (43.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SNDX is forecast to be unprofitable in 3 years.

Syndax Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 197%

Consensus revenue estimates fall by 21%

Consensus revenue estimates increase by 12%

Consensus EPS estimates fall by 23%

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus EPS estimates fall by 21%

Recent updates

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Consensus revenue estimates increase by 197%

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 11%, EPS upgraded

Director exercised options and sold US$715k worth of stock

Director exercised options and sold US$794k worth of stock

Syndax Pharmaceuticals, Inc. Announces Executive Changes

President exercised options and sold US$695k worth of stock

President exercised options and sold US$853k worth of stock

Consensus EPS estimates fall by 21%

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Price target increased by 7.6% to US$34.44

Independent Director exercised options and sold US$616k worth of stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Consensus revenue estimates increase by 64%

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CEO & Director exercised options and sold US$549k worth of stock

President exercised options and sold US$4.4m worth of stock

Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock

Consensus forecasts updated

Independent Director exercised options and sold US$331k worth of stock

First half 2022 earnings released

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors